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Abstract
Several reports have shown that statin treatment benefits patients with asthma, however 
inconsistent effects have been observed. The mir-152 family (148a, 148b and 152) has been 
implicated in asthma. These microRNAs suppress HLA-G expression, and rs1063320, a common 
SNP in the HLA-G 3’UTR which is associated with asthma risk, modulates miRNA binding. We 
report that statins up-regulate mir-148b and 152, and affect HLA-G expression in an rs1063320 
dependent fashion. In addition, we found that individuals who carried the G minor allele of 
rs1063320 had reduced asthma related exacerbations (emergency department visits, 
hospitalizations or oral steroid use) compared to non-carriers (p=0.03) in statin users ascertained 
in the Personalized Medicine Research Project at the Marshfield Clinic (n=421). These findings 
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support the hypothesis that rs1063320 modifies the effect of statin benefit in asthma, and thus may 
contribute to variation in statin efficacy for the management of this disease.
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INTRODUCTION
Statins, or HMG-CoA reductase inhibitors, which are primarily prescribed for the reduction 
of cardiovascular disease, have well-documented anti-inflammatory effects attributed to the 
inhibition of both isoprenoid production and prenylation of inflammatory signaling 
molecules [1]. Thus, statins may be of benefit in the prevention and treatment of asthma, a 
disease in which inflammation is of central importance [2–5]. Statin exposure has been 
associated with a reduction in asthma-related hospitalizations, attenuation in the decline of 
lung function in the elderly and in smokers, and a reduction in the number of Chronic 
Obstructive Pulmonary Disease (COPD) exacerbations [6–13]. For example, a retrospective 
cohort study of over 12 million members within the Medco Health Solutions National 
Integrated database found that adult with asthma and concomitant statin and inhaled 
corticosteroid therapy had a 33% lower risk of emergency department (ED) visits for asthma 
compared to non-statin users after adjustment for potential confounding variables [14]. 
However, two small trials failed to demonstrate improvement in indices of asthma status 
with statin treatment [15, 16], leading some to question the potential benefit of statins for 
asthma management [17]. This inconsistency may have a genetic basis as the considerable 
variability in both the lipid lowering and anti-inflammatory effects of statins is partly due to 
genetic factors [18, 19].
HLA-G, a non-classic class I HLA molecule with important immunomodulatory properties, 
has been associated with asthma in multiple independent populations [20–23]. Although the 
precise mechanism underlying this relationship is unknown, both HLA-G transcript and 
protein levels have been reported to be increased in the lung and plasma of subjects with 
asthma [24–26]. In addition, a common SNP (rs1063320 aka HLA-G +3142, 0.46 minor 
allele frequency,) within the 3’ UTR of the HLA-G gene has been associated with reduced 
risk of asthma in the children of mothers with asthma [27]. Notably, rs1063320 disrupts the 
targeting of the mir-152 family (mir-148a, mir-148b and mir-152) to the HLA-G gene such 
that these microRNAs can only down-regulate HLA-G transcripts carrying the variant G 
allele, with no effect on transcripts with the C allele. Furthermore, adult asthmatic patients 
with an asthmatic mother were also shown to have elevated mir-148b levels in airway 
epithelial cells, and greater soluble HLA-G (sHLA-G) in brochoalveolar lavage fluid in GG 
homozygotes compared to non-carriers [28]. Thus these results support the hypothesis that 
allele-specific targeting of mir-148a, mir-148b, and/or mir-152 may contribute to the 
association of the HLA-G gene with the risk of asthma.
In this study, we report that statin treatment up-regulates expression of mir-148a, mir-148b 
and mir-152 in vitro, leading to the hypothesis that statin treatment may benefit asthmatic 
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patients that carry the HLA-G G allele by causing a reduction of HLA-G expression in these 
subjects. Thus, we sought to test if rs1063320 modifies statin effects on asthma-related 
exacerbations in a population-based cohort of statin users identified from the Marshfield 
Clinic Personalized Medicine Research Program (PMRP).
MATERIALS, SUBJECTS AND METHODS
Cell culture
Immortalized lymphoblastoid cell lines (LCLs) established from participants of the 
Cholesterol and Pharmacogenetics (CAP) clinical trial were grown under standard 
conditions in RPMI supplemented with 10% FBS and either 2.0µM activated simvastatin or 
sham buffer for 24 hours as previously described[29]. 5×106 HepG2 cells were exposed in 
replicate to DMEM supplemented with 10% FBS and either 2.0µM activated simvastatin or 
sham buffer for 24 hours. Simvastatin was obtained as a gift from Merck, and activated as 
previously described [29].
Gene expression measurements
Total RNA was extracted using the mirVana RNA isolation kit (Ambion, Austin, TX), 
quantified by NanoDrop (Thermo Scientific, Waltham, MA), and RNA integrity was 
assessed on the Agilent Technologies 2100 Bioanalyzer. HLA-G was quantified by 
expression array (GEO accession number: GSE36868) as previously described [30]. 
mir-148a, mir-148b and mir-152 were quantified by real-time PCR using TaqMan 
MicroRNA Assays (assay IDs 000470, 000471 and 000475 respectively) according to the 
manufacturer’s protocol (Applied Biosystems, Foster City, CA). All reactions were 
performed in triplicate and run on an Applied Biosystems 7900HT Fast Real-Time PCR 
System. microRNA expression levels were normalized against mir-25, whose expression is 
unchanged with statin exposure (Figure S1). Statin-induced change in mir-148a, mir-148b 
and mir-152 was calculated using the delta delta Ct method. Paired two-side t-tests were 
used to identify differences in HLA-G and miRNA expression levels with statin treatment. 
HLA-G and microRNA expression levels quantified in LCLs were quantile normalized, split 
by rs1063320 genotype group, and tested for correlation using linear regression.
HLA-G protein quantitation
Soluble HLA-G protein levels were quantified by ELISA (BioVendor, Candler, NC) in cell 
culture media from in vitro 2.0µM simvastatin versus sham exposed LCLs. All 
measurements were performed in duplicate and averaged.
Genotyping
Donors of CAP LCLs were subject to genome-wide genotyping on the Illumina 
HumanHap300 or HumanHap610-Quad genotyping platforms (dbGaP accession number: 
phs000481), and rs1063320 was imputed as previously described[31]. Genotypes with an 
imputed probability less than 0.85 were omitted from the analyses. rs1063320 was directly 
genotyped with a TaqMan SNP Genotyping assay (Applied Biosystems).
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Study Subjects
Study subjects were ascertained from the Personalized Medicine Research Project at the 
Marshfield Clinic in Wisconsin, population-based biobank. PMRP is comprised of 20,000 
non-Hispanic whites of Northern European descent (98%) from Central Wisconsin. 
Enrollment was conducted in accordance with the guidelines established by the Institutional 
Review Boards of the Marshfield Clinic Research Foundation. Access and evaluation of the 
PMRP was performed through the Pharmacogenomics Discovery and Replication in Large 
Populations (PGPop) Consortium.
We identified individuals with asthma using ICD-9 codes (493*), with diagnoses indicated 
on two separate days. We have previously demonstrated that requiring the presence of such 
codes on two separate days substantially increases phenotypic accuracy (>95%) and 
replication for known genetic signals [34, 35]. Exclusion criteria for both cohorts included 
any individual with a single diagnosis code for chronic obstructive pulmonary disease (496), 
cystic fibrosis (277*), immunodeficiency (279*), bronchiectasis (494*), hereditary and 
degenerative diseases of CNS (331), mental retardation (317, 318, 319), congestive heart 
failure (428*, 429.9), pulmonary hypertension or embolism (415*, 416*, 417*), lupus 
(710.0), RA (714.0), tuberculosis (511.1), lung cancer (162*), or sarcoidosis (135). These 
algorithms were validated by manual chart review of 50–100 records per cohort and found 
to have >90% PPV.
Statin users were then identified as individuals with at least two mentions of statin drugs 
(simvastatin, fluvastatin, pravastatin, rosuvastatin, atorvastatin, lovastatin or any brand 
names of these drugs) of the same type and dose within a 6-month time window. We have 
previously demonstrated the capacity of natural language processing to document statin 
exposure since this type of data can generate accurate dose response curves despite the lack 
of information regarding drug compliance [36]. Statin users with asthma were defined as 
those with asthma drug use or diagnosis indicated after the date of first statin mention. From 
this analysis we identified 421 subjects (Tables S1 and S2).
Case definition
Asthma related exacerbations were defined as emergency department visits, hospitalizations, 
and/or use of oral steroids (prednisone, methylprednisone, solumedrol, solu-medrol, orapred, 
orasone, medrol, depo-medrol, depomedrol, depopred, prednisolone) for which an ICD-9 
code for asthma or wheezing (786.07) appeared in the medical record concurrently. Since a 
high percentage of individuals cease statin use within the first year of prescription, to 
increase the likelihood that identified individuals were still on statin during the time of the 
exacerbation, we only included exacerbations that occurred within 6 months (+/− 180 days) 
of a statin mention in the EMR. This algorithm had a >90% PPV.
Covariate definition
All prescription information, as well as weight, height and smoking status was collected for 
evaluation as a potential confounding variable. Smoking status was divided into three 
categories: “current”, “former” or “never smoker”. Confirmed use was validated in a subset 
of charts by manual review. Subjects were classified as having inhaled corticosteroid (ICS) 
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use if they were prescribed beclomethasone, budesonide, budesonide/formoterol, 
ciclesonide, flunisolide, fluticasone, fluticasone/salmeterol, mometasone, mometasone/
formoterol, triamcinolone.
Statistical Analyses
A general linear model was used to test for a relationship between rs1063320 and statin 
effects on number of exacerbations (treated as a continuous variable), and included 
adjustment for gender, smoking status and ICS use. All analyses were performed in JMP 9.1 
(SAS Institute, Cary, NC) using an additive model.
RESULTS
Mir-148b and mir-152 are statin responsive and correlated to HLA-G in an rs1063320 
dependent fashion
To determine if mir-148a, mir-148b or mir-152 transcript levels are statin responsive, we 
incubated both LCLs (n=48) and HepG2 cell lines (n=6 replicate experiments) with either 
2.0µM simvastatin or sham buffer for 24 hours, and quantified changes in transcript levels 
using real-time PCR. Mir-148b and mir-152 were upregulated with statin treatment in both 
cell types (p<0.05, Figure 1A). No change in mir-148a levels was detected.
The rs1063320 C allele has been previously reported to disrupt the binding sites of mir-148 
and mir-152 in the HLA-G 3’ UTR[27]. Using previously collected genotype data for the 
LCLs, we confirmed that the C allele carriers had 1.3-fold greater HLA-G transcript 
(p<0.0001, N=160) than non-carriers (Figure 1B). Furthermore, we found that inter-
individual variation in microRNA and HLA-G transcript levels was correlated in the LCLs in 
an rs1063320 dependent fashion. Specifically, lower expression levels of mir-148a and 152 
were correlated with higher HLA-G transcript levels, but only in the LCLs derived from 
rs1063320 GG homozygotes (p<0.05, n=11). No correlation was seen in LCLs from either 
CC or CG rs1063220 donors (n=15, Figure 1C). A similar, non-statistically significant, trend 
was observed between mir-148b and HLA-G.
It has been previously suggested that the mir-152 family regulates HLA-G by impacting 
translation and not mRNA decay [28]. Thus, we quantified both HLA-G transcript and 
sHLA-G protein levels in LCLs after 24hr in vitro incubation with 2.0µM simvastatin or 
sham buffer. While we detected no change in HLA-G transcript levels in LCLs that carried 
the C allele, we found that statin treatment increased HLA-G transcripts levels (p=0.01, 
Figure 1B) in the GG homozygotes. In contrast, we observed a reduction in HLA-G protein 
levels in both genetic groups, but there was a trend (p=0.09) of greater reductions of HLA-G 
protein in the GG versus CC homozygotes (Figure S2). These findings are consistent with 
our hypothesis that rs1063320 modifies statin effects on HLA-G expression.
rs1063320 genotype is associated with frequency of exacerbations in statin users
To test our hypothesis that statins may benefit asthma in an rs1063320 dependent fashion, 
we used logistic regression with adjustment for significantly associated covariates (see 
Methods). Consistent with our hypothesis, we found that individuals who carried at least one 
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copy of the G minor allele had a reduced frequency of asthma-related exacerbations 
(emergency department visits, hospitalizations or oral steroid use) compared to non-carriers 
using an additive genetic model (p=0.03), Figure 2. There was no difference in exacerbation 
frequency between GG and CG genotypes.
DISCUSSION
We report evidence that statin treatment increases expression of mir-148b and mir-152, has 
no impact on HLA-G transcript in rs1063320 CC homozygotes, and appears to cause greater 
reductions in HLA-G protein levels in GG homozygotes. HLA-G expression is regulated by 
the mir-152 family of microRNAs (mir-148a, mir-148b and mir-152), and rs1063320 is 
thought to disrupt this interaction [27, 28, 38]. Since HLA-G levels are increased in 
asthmatic patients, our identification that statin treatment up-regulates mir-148b and mir-152 
and influences HLA-G expression in a rs1063320 dependent manner lead to our hypothesis 
that statin treatment may show greater benefit in individuals with the rs1063320 G allele 
(Figure 3). Consistent with this hypothesis, we observed that asthmatic patients with at least 
one copy of the G allele had a reduced frequency of exacerbations while on statin compared 
to CC homozygotes. Given the immunomodulatory properties of HLA-G, it has been 
proposed that understanding gene regulation and the role of polymorphisms (especially 
those in the 3’ UTR) in HLA-G may help inform the development of personalized medicine 
[39]. Specifically, rs1063320 is only one of two HLA-G SNPs proposed to have clinical 
potential, and assays have been developed for quick typing of this polymorphic site [40, 41].
Nicodemus-Johnson et al (2013) recently reported that asthmatic patients with the 
rs1063320 G allele had reduced sHLA-G in BAL fluid compared to non-carriers [28]. 
Consistent with this report, we also found that LCLs homozygous for the G allele had 
reduced sHLA-G protein levels compared to CC homozygotes. Interestingly, they did not 
identify a statistically significant association between the SNP and HLA-G transcript in the 
bronchial epithelial cells themselves. In addition, Zhu et al (2010) demonstrated that 
mir-152 overexpression caused reduced HLA-G protein levels by targeting the 3’ UTR, but 
had no effect on HLA-G transcript levels [38], leading to the suggestion that the mir-152 
family modulates HLA-G at the level of protein translation rather than mRNA decay. Here, 
we report disparate effects of statin treatment on HLA-G transcript versus protein levels in 
the rs1063320 GG homozygotes, consistent with the possibility that mir-148 and mir-152 
may influence HLA-G translation. It is possible that the increase in HLA-G transcript levels 
in the GG homozygotes after statin treatment is due to a compensatory upregulation of gene 
transcription if statin treatment attenuates transcript translation. However, our identification 
of an association between rs1063320 and HLA-G transcript levels, along with the negative 
correlation observed between mir-148a, mir-148b and mir-152 expression levels with HLA-
G transcripts, strongly suggest that these microRNAs modulate HLA-G transcript levels as 
well. Thus, further studies are required to ascertain the exact mechanism by which the 
mir-152 family regulates HLA-G.
Recently it has been called into question whether rs1063320 modifies mir-148a, mir-148b 
and/or mir-152 regulation of HLA-G. It has been independently reported that mir-148 and 
mir-152 overexpression reduces HLA-G by targeting its 3’ UTR [38, 42], and that this 
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targeting impacts HLA-G function [42]. Although Tan et al (2007) originally reported that 
rs1063320 modulated luciferase expression from a HLA-G 3’ UTR reporter construct in the 
context of mir-148a, mir-148b and mir-152 overexpression, Manaster et al (2012) failed to 
replicate this finding [27, 42]. Although our results are consistent with the possibility that 
rs1063320 directly impacts HLA-G regulation, we did not test it directly. Thus, it is possible 
that the associations observed in the LCLs between rs1063320 with HLA-G transcript and 
protein in both the statin and sham treated states are mediated by an alternate SNP in high 
linkage disequilbrium with rs1063320.
Statin use has been associated with reduced COPD related exacerbations as well as overall 
lower mortality [11, 43–45]. Although there is currently no literature supporting a link 
between COPD and HLA-G, levels of both mir-148a and mir-152 has been reported 
independently to be differentially expressed in subjects with COPD [46–48], suggesting that 
HLA-G may also play a role in COPD. Thus, it is possible that rs1063320 may modulate 
statin benefit in COPD as well.
Despite the strengths of our study, there are a number of caveats to our results. First, all 
subjects included in the study received statin treatment during the course of routine clinical 
care, and statin users were identified by natural language processing of the electronic 
medical records. Thus, we have no direct measures of drug compliance or pharmacy 
information. However, we did require that the same statin type and dose were mentioned 
twice in the EMR within a 6-month time window to increase the likelihood that individuals 
were dose-stabilized and drug compliant. Furthermore, we extensively validated our 
algorithms using chart review. We have previously used such techniques to identify genetic 
variation associated with LDL cholesterol response to statin treatment [36]. Second, 
although we were able to identify a statistically significant association between rs1063320 
and asthma-related exacerbations in statin users, replication in independent cohorts is 
necessary to confirm this association. Notably, using the same algorithms described above, 
we identified 453 asthmatic statin users in BioVU, a population based biobank at the 
Vanderbilt University Medical Center in Tennessee. However, only 6 of the 453 subjects 
identified had a documented exacerbation after the start of statin use, and thus this cohort 
was severely underpowered to test for replication. Third, we were not able to control for all 
known covariates. For example, the relationship between rs1063320 and asthma status has 
been shown to be dependent on maternal asthma status, and we were unable to reliably 
extract this information from the EMR [27, 28]. In addition, smoking status is particularly 
challenging to evaluate based on health records alone [49].
Although the rs1063320 C allele is the ancestral allele, its frequency varies between 
populations: 45.6% in Northern Europeans (CEPH), 58.1% in Han Chinese, 65.5% in 
Yorubans and 73.3% in Japanese. Thus, if it is successfully validated that the C allele 
reduces statin benefits for asthma, given the high prevalence of this variant across the global 
population, these results could help explain discrepancies in studies of statin effects on the 
severity of these diseases. Importantly, such a relationship could identify a substantial 
number of asthmatics worldwide for whom statins may be a viable treatment alternative. 
However, the current results should be considered preliminary observations and are not 
intended to guide current statin prescription.
Naidoo et al. Page 7
Pharmacogenomics J. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
In summary, statins up-regulated mir-148b and mir-152, and affect HLA-G expression while 
modulated by rs1063320. Consistent with this mechanism, we observed that rs1063320 is 
associated with frequency of asthma-related exacerbations in statin users. These results 
provide support for genetically-influenced heterogeneity of treatment response to statins for 
individuals with asthma. Importantly, rs1063320 genotype could inform future statin use, 
thus introducing another therapeutic option for the management of asthma.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. mir-152 family and HLA-G expression levels are statin responsive
A) CAP LCLs (n=48) and HepG2 (n=6 replicate experiments) cells were incubated with 2.0 
µM simvastatin or sham buffer for 24 hours, and mir-148a, 148b and 152 were quantified by 
qPCR, with values normalized against mir-25. Values shown are fold change (statin/sham 
values) ± standard error, *p<0.05. B) Normalized HLA-G transcript level was quantified by 
expression array in statin or sham treated LCLs (CC n=32, CG n=42, GG n=86) as 
previously described[30] and tested for association with rs1063320 genotype using an 
additive model. C) Expression levels of HLA-G and the three microRNAs were measured in 
sham treated LCLs, quantile normalized, and tested for correlation across the samples split 
by rs1063320 genotype: GG n=11, CC or CG n=15.
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Figure 2. Association between rs1063320 and asthma-related exacerbations
rs1063320 genotype and frequency of asthma-related exacerbations in statin users was tested 
using an additive general linear model with adjustment for smoking status, gender and 
inhaled corticosteroid use (p=0.03). A post-hoc student’s t-test was used to identify 
differences between genotypic groups as indicated by “a” or “b”. CC n=111, CG n=204, GG 
n=106. Values shown are least square means ± standard error.
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Figure 3. Hypothetical model
Statin treatment up-regulates mir-148b and mir-152, which target the HLA-G 3’UTR in an 
rs1063320 dependent fashion, leading to the prediction that statin treatment has greater 
benefit in individuals with asthma that carry the rs1063320 G allele.
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Table 1
PMRP Subject characteristics
N 421
Age (median) 52
% Male 34.2
% Inhaled corticosteroid use 66.7
% Non-smoker (never) 51.4
% With exacerbation (1, 2 or 3)* 2.8
Statin Type**
Simvastatin (%) 26.4
Lovastatin (%) 9.0
Pravastatin (%) 5.2
Fluvastatin (%) 3.5
Atorvastatin (%) 54.5
Rosuvastatin (%) 1.4
*
Exacerbation defined as asthma-related ER visit, hospitalization or oral steroid use that occurred within 6 months of a statin mention in the EMR.
**
Either type of statin listed just prior to exacerbation, or first known statin in those without an exacerbation within 6 months of the first statin 
mention.
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